Present Status and Problems on Molecular Targeted Therapy of Cancer

키워드

참고문헌 (50)

1. Weinstein IB, "Mechanisms of disease : oncogene addiction-a rationale for molecular targeting in cancer therapy", Nat Clin Pract Oncol, 3, pp.448~457 (2006)
2. Jackman DM, "Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated nonsmall cell lung cancer patients : results of an online tumor registry of clinical trials", Clin Cancer Res, 15, pp.5267~5273 (2009)
3. Kwak EL, "Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer", N Engl J Med, 363, pp.1693~1703 (2010)
4. Chapman PB, "Phase III randomized open label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma", J Clin Oncol, 29(S), pp.LBA4~ (2011)
5. [URL]
6. Paez JG, "EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy", Science, 304, pp.1497~1500 (2004)
7. Lynch TJ, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib", N Engl J Med, 350, pp.2129~2139 (2004)
8. Siehl J, "C-kit, GIST, and imatinib", Recent Results Cancer Res, 176, pp.145~151 (2007)
9. Mitsudomi T, "Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer", Cancer Sci, 98, pp.1817~1824 (2007)
10. Flaherty KT, "Inhibition of mutated, activated BRAF in metastatic melanoma", N Engl J Med, 363, pp.809~819 (2010)
11. Soda M, "Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer", Nature, 448, pp.561~566 (2007)
12. Marchetti A, "Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations", J Clin Oncol, 29, pp.3574~3579 (2011)
13. Choi YL, "EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors", N Engl J Med, 363, pp.1734~1739 (2010)
14. Sasaki T, "A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors", Cancer Res, 71, pp.6051~6060 (2011)
15. Saijo N, "Critical comments for roles of biomarkers in the diagnosis and treatment of cancer", Cancer Treat Rev, 38, pp.63~67 (2012)
16. Sequist LV, "Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors", Sci Transl Med, 3, pp.75~26 (2011)
17. Rehman FL, "Synthetic lethal approaches to breast cancer therapy", Nat Rev Clin Oncol, 7, pp.718~724 (2010)
18. Farmer H, "Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy", Nature, 434, pp.917~921 (2005)
19. Bryant HE, "Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose)polymerase", Nature, 434, pp.913~917 (2005)
20. McCabe N, "BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly(ADP-Ribose)polymerase : an issue of potency", Cancer Biol Ther, 4, pp.934~936 (2005)
21. McCabe N, "Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose)polymerase inhibition", Cancer Res, 66, pp.8109~8115 (2006)
22. Ledermann JA, "Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serious ovarian cancer (PSR SOC)", J Clin Oncol, 29(S), pp.5003~ (2011)
23. O'Shaughnessy J, "Iniparib plus chemotherapy in metastatic triple-negative breast cancer", N Engl J Med, 364, pp.205~214 (2011)
24. O’Shaughnessy J, "A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine", carboplatin (G, J Clin Oncol, pp.2011, 29(S)[DOI]
25. Pal SK, "Triple negative breast cancer : unmet medical needs", Breast Cancer Res Treat, 125, pp.627~636 (2011)
26. "Problems involved in the clinical trials for non-small cell lung carcinoma"[URL]
27. Miller KD, "Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer", J Clin Oncol, 23, pp.792~799 (2005)
28. Miller K, "Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer", N Engl J Med, 357, pp.2666~2676 (2007)
29. Miles DW, "Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer", J Clin Oncol, 28, pp.3239~3247 (2010)
30. Robert NJ, "RIBBON-1 : randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer", J Clin Oncol, 29, pp.1252~1260 (2011)
31. Meyerhardt JA, "Systemic therapy for colorectal cancer", N Engl J Med, 352, pp.476~487 (2005)
32. Hurwitz HI, "Bevacizumab in combination with fluorouracil and leucovorin : an active regimen for first-line metastatic colorectal cancer", J Clin Oncol, 23, pp.3502~3508 (2005)
33. Saltz LB, "Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer : a randomized phase III study", J Clin Oncol, 26, pp.2013~2019 (2008)
34. Allegra CJ, "Initial safety report of NSABP C-08 : A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer", J Clin Oncol, 27, pp.3385~3390 (2009)
35. Sandler A, "Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer", N Engl J Med, 355, pp.2542~2550 (2006)
36. Reck M, "Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer : AVAil", J Clin Oncol, 27, pp.1227~1234 (2009)
37. Escudier B, "Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma : a randomised, double-blind phase III trial", Lancet, 370, pp.2103~2111 (2007)
38. 라선영, "Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study", JOURNAL OF CLINICAL ONCOLOGY, 29(30), pp.3968~3976, AMER SOC CLINICAL ONCOLOGY
39. Burger RA, "Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study", J Clin Oncol, 28(18S), pp.LBA1~ (2010)
40. Kristensen G, "Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer", J. Clin Oncol, 29(S), pp.LBA5006~ (2011)
41. Aghajanian C, "Oceans: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoncal, or fallopian tube cancer", J Clin Oncol, 29(S), pp.LBA5007~ (2011)
42. Gray R, "Independent review of E2100 : a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer", J Clin Oncol, 27, pp.4966~4972 (2009)
43. Burstein HJ, "Bevacizumab for advanced breast cancer: all tied up with a RIBBON?", J Clin Oncol, 29, pp.1232~1235 (2011)
44. Shepherd FA, "Erlotinib in previously treated non-small-cell lung cancer", N Engl J Med, 353, pp.123~132 (2005)
45. Mok TS, "Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
46. Kim ES, "Gefitinib versus docetaxel in previously treated non-small-cell lung cancer(INTEREST) : a randomised phase III trial", Lancet, 372, pp.1809~1818 (2008)
47. Schiller JH, "Results of ARQ 197-209: a global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naïve patients with locally advanced metastatic non-small cell lung cancer (NSCLC)", J Clin Oncol, 28(18S), pp.LBA7502.~ (2010)
48. Kantoff PW, "Sipuleucel-T immunotherapy for castration-resistant prostate cancer", N Engl J Med, 363, pp.411~422 (2010)
49. Hodi FS, "Improved survival with ipilimumab in patients with metastatic melanoma", N Engl J Med, 363, pp.711~723 (2010)
50. Robert C, "Ipilimumab plus dacarbazine for previously untreated metastatic melanoma", N Engl J Med, 364, pp.2517~2526 (2011)

관련 논문AI추천